As resistance to targeted agents such as BRAF and EGFR inhibitors remains a significant clinical problem in CRC [4, 10, 13, 44], we also investigated potential mechanisms of resistance to LY3009120 using a KRASmut CRC cell line. Here, EGFR is linked to colorectal carcinoma.